These data demonstrate the strong antigen-specific selection pressure on tumor cells by gp100-specific CD8+ Teff after gp100 vaccination and NKTR-214, and support the notion that anticancer vaccines for patients with cancer will ideally target multiple tumor-associated antigens to minimize tumor escape through single antigen loss. Here, CD8A is linked to neoplasm.